Premium
Artificially low mild cognitive impairment to normal reversion rate in the Alzheimer's Disease Neuroimaging Initiative
Author(s) -
Thomas Kelsey R.,
Eppig Joel S.,
Weigand Alexandra J.,
Edmonds Emily C.,
Wong Christina G.,
Jak Amy J.,
DelanoWood Lisa,
Galasko Douglas R.,
Salmon David P.,
Edland Steven D.,
Bondi Mark W.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.10.008
Subject(s) - reversion , dementia , neuroimaging , disease , alzheimer's disease neuroimaging initiative , cognition , alzheimer's disease , psychology , cognitive impairment , mean reversion , clinical dementia rating , audiology , medicine , pediatrics , psychiatry , biochemistry , chemistry , financial economics , economics , gene , phenotype
Abstract Introduction We examined reasons for low mild cognitive impairment (MCI)‐to‐cognitively normal (CN) reversion rates in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Methods CN and MCI participants were identified as remaining stable, progressing, or reverting at 1‐year of follow‐up (Year 1). Application of ADNI's MCI criteria at Year 1 in addition to Alzheimer's disease biomarkers by group were examined. Results The MCI‐to‐CN reversion rate was 3.0%. When specific components were examined, 22.5% of stable MCI participants had normal memory performance at Year 1 and their Alzheimer's disease biomarkers were consistent with the stable CN group. At Year 1, when all MCI criteria were not met, the more subjective Clinical Dementia Rating rather than objective memory measure appeared to drive continuation of the MCI diagnosis. Discussion Results demonstrate an artificially low 1‐year MCI‐to‐CN reversion rate in ADNI‐diagnosed participants. If the Logical Memory cutoffs had been consistently applied, the reversion rate would have been at least 21.8%.